Generic inhalation company Nephron Pharmaceuticals Corporation revealed on Tuesday the addition of John Singerling, III as the inaugural member of its newly established Senior Advisory Board.
The company disclosed that the mission of this board is to promote generic medication usage to lower the rising cost of healthcare and promote opioid free pain management as a solution to the current US crisis. Singerling's extensive background in hospital administration and years of healthcare service uniquely qualify him as an industry strategist.
Since joining Palmetto Health in 1996, Singerling has served as its administrative fellow, chief operating officer at Palmetto Health Richland, president of Palmetto Health as well as president of Prisma Health-Midlands.
According to the company, Singerling graduated from the USC graduate programme in Health Administration.
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling